MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells

• DOI: 10.18632/oncotarget.22818
• Publication Date: 2017-12-01T17:54:45Z
• Authors: Hyebin Koh; Hyeri Park; Nisansala Chandimali; Do Luong Huynh; Jiao Jiao Zhang; Mrinmoy Ghosh; Meeta Gera; Nameun Kim; Yesol Bak; Do-Young Yoon; Yang Ho Park; Taeho Kwon; Dong Kee Jeong
• Keywords: MUC1

The existence of cancer stem cells (CSCs) is the main reason for failure treatment caused by drug resistance. Therefore, eradicating cancers targeting CSCs remains a significant challenge. In present study, because important role BMI-1 proto-oncogene, polycomb ring finger (BMI-1) and C-terminal Mucin1 (MUC1-C) in tumor growth maintenance CSCs, we aimed to confirm that microRNA miR-128, as an inhibitor MUC1-C, could effectively suppress paclitaxel (PTX)-resistant lung cells. We showed have significantly higher expression levels BMI-1, stemness proteins, signaling factors, malignancy compared with normal After transfection MUC1-C were suppressed. When miR-128 was stably expressed PTX-resistant cells, decreased proliferation, metastasis, self-renewal, migration, invasive ability, clonogenicity, tumorigenicity vitro vivo increased apoptosis miR-NC (negative control) CSCs. Furthermore, β-catenin intracellular pathway-related factors MiR-128 also luciferase activity MUC1 reporter constructs reduced transmembrane BMI-1. These results suggested attractive therapeutic strategy via inhibition MUC1-C.